The safety of human pluripotent stem cells in clinical treatment

Annals of Medicine

Volumn 47, Issue 5, 2015, Pages 370-380

  Simonson, Oscar E ^a   Domogatskaya, Anna ^a,b   Volchkov, Pavel ^c,d   Rodin, Sergey ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Imtek Limited   (Russian Federation)

^c Harvard University   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Epigenetic aberrations; good manufacturing practices; human embryonic stem cells (hESCs); human induced pluripotent stem cells (hiPSCs); human nuclear transfer embryonic stem cells (NT ESCs); human pluripotent stem cells (hPSCs); immune rejection; parthenogenetic human embryonic stem cells (phESCs); stem cell bank; tumorigenicity

Indexed keywords

COLLAGEN TYPE 4; LAMININ; MATRIGEL; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN; HLA ANTIGEN;

ALLOGRAFT; CARCINOGENICITY; CELL NUCLEUS TRANSPLANTATION; EMBRYONIC STEM CELL; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT REJECTION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOGENICITY; LEGAL ASPECT; PATIENT SAFETY; PLURIPOTENT STEM CELL; PLURIPOTENT STEM CELL LINE; PLURIPOTENT STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL CULTURE; STEM CELL TRANSPLANTATION; CELL LINE; CELL TRANSFORMATION; CLINICAL TRIAL (TOPIC); CULTURE TECHNIQUE; CYTOLOGY; ETHICS; GENETIC EPIGENESIS; HEALTH CARE FACILITY; IMMUNOLOGY; LEGISLATION AND JURISPRUDENCE; REGENERATIVE MEDICINE; STEM CELL RESEARCH; TRANSPLANTATION;

BIOLOGICAL SPECIMEN BANKS; CELL CULTURE TECHNIQUES; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; GRAFT REJECTION; HLA ANTIGENS; HUMANS; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; STEM CELL RESEARCH;

EID: 84940053201     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2015.1051579     Document Type: Review

References (99)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998 6; 282: 1145-7.
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131: 861-72.
3. Revazova ES, Turovets NA, Kochetkova OD, Kindarova LB, Kuzmichev LN, Janus JD, et al. Patient-specific stem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells. 2007; 9: 432-49.
4. Tachibana M, Amato P, Sparman M, Gutierrez NM, Tippner-Hedges R, Ma H, et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell. 2013; 153: 1228-38.
5. Klimanskaya I, Chung Y, Becker S, Lu SJ, Lanza R. Human embryonic stem cell lines derived from single blastomeres. Nature. 2006; 444: 481-5.
6. Chung Y, Klimanskaya I, Becker S, Li T, Maserati M, Lu SJ, et al. Human embryonic stem cell lines generated without embryo destruction. Cell Stem Cell. 2008; 2: 113-17.
7. Rodin S, Antonsson L, Niaudet C, Simonson OE, Salmela E, Hansson EM, et al. Clonal culturing of human embryonic stem cells on laminin-521/E-cadherin matrix in defined and xeno-free environment. Nat Commun. 2014; 5: 3195.
8. Revazova ES, Turovets NA, Kochetkova OD, Agapova LS, Sebastian JL, Pryzhkova MV, et al. HLA homozygous stem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells. 2008; 10: 11-24.
9. Daughtry B, Mitalipov S. Concise review: parthenote stem cells for regenerative medicine: genetic, epigenetic, and developmental features. Stem Cells Transl Med. 2014; 3: 290-8.
10. Isasi RM, Knoppers BM. Monetary payments for the procurement of oocytes for stem cell research: in search of ethical and political consistency. Stem Cell Res. 2007; 1: 37-44.
11. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011; 8: 409-12.
12. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010; 7: 618-30.
13. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci. 2009; 85: 348-62.
14. Ohi Y, Qin H, Hong C, Blouin L, Polo JM, Guo T, et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat Cell Biol. 2011; 13: 541-9.
15. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011; 471: 68-73.
16. Nazor KL, Altun G, Lynch C, Tran H, Harness JV, Slavin I, et al. Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. Cell Stem Cell. 2012; 10: 620-34.
17. Ruiz S, Diep D, Gore A, Panopoulos AD, Montserrat N, Plongthongkum N, et al. Identification of a specific reprogramming-associated epigenetic signature in human induced pluripotent stem cells. Proc Natl Acad Sci USA. 2012; 109: 16196-201.
18. Ma H, Morey R, ONeil RC, He Y, Daughtry B, Schultz MD, et al. Abnormalities in human pluripotent cells due to reprogramming mechanisms. Nature. 2014; 511: 177-83.
19. Foldes G, Matsa E, Kriston-Vizi J, Leja T, Amisten S, Kolker L, et al. Aberrant ?-Adrenergic hypertrophic response in cardiomyocytes from human induced pluripotent cells. Stem Cell Reports. 2014; 3: 905-14.
20. Takahashi K, Yamanaka S. Induced pluripotent stem cells in medicine and biology. Development. 2013; 140: 2457-61.
21. Deuse T, Wang D, Stubbendorff M, Itagaki R, Grabosch A, Greaves LC, et al. SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts. Cell Stem Cell. 2015; 16: 33-8.
22. Andrews PW, Cavanagro J, Deans R, Feigel E, Horowitz E, Keating A, et al. Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells. Nat Biotechnol. 2014; 32: 724-6.
23. Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011; 29: 1132-44.
24. Narva E, Autio R, Rahkonen N, Kong L, Harrison N, Kitsberg D, et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol. 2010; 28: 371-7.
25. Cooke MJ, Stojkovic M, Przyborski SA. Growth of teratomas derived from human pluripotent stem cells is influenced by the graft site. Stem Cells Dev. 2006; 15: 254-9.
26. Hovatta O, Rodin S, Antonsson L, Tryggvason K. Concise review: animal substance-free human embryonic stem cells aiming at clinical applications. Stem Cells Transl Med. 2014; 3: 1269-74.
27. Martin MJ, Muotri A, Gage F, Varki A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med. 2005; 11: 228-32.
28. Hovatta O, Mikkola M, Gertow K, Stromberg AM, Inzunza J, Hreinsson J, et al. A culture system using human foreskin fibroblasts as feeder cells allows production of human embryonic stem cells. Hum Reprod. 2003; 18: 1404-9.
29. Inzunza J, Gertow K, Stromberg MA, Matilainen E, Blennow E, Skottman H, et al. Derivation of human embryonic stem cell lines in serum replacement medium using postnatal human fibroblasts as feeder cells. Stem Cells. 2005; 23: 544-9.
30. Ludwig TE, Levenstein ME, Jones JM, Berggren WT, Mitchen ER, Frane JL, et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol. 2006; 24: 185-7.
31. Braam SR, Zeinstra L, Litjens S, Ward-van Oostwaard D, van den Brink S, van Laake L, et al. Recombinant vitronectin is a functionally defined substrate that supports human embryonic stem cell self-renewal via alphavbeta5 integrin. Stem Cells. 2008; 26: 2257-65.
32. Rodin S, Domogatskaya A, Strom S, Hansson EM, Chien KR, Inzunza J, et al. Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. Nat Biotechnol. 2010; 28: 611-15.
33. Zhang R, Mjoseng HK, Hoeve MA, Bauer NG, Pells S, Besseling R, et al. A thermoresponsive and chemically defined hydrogel for long-term culture of human embryonic stem cells. Nat Commun. 2013; 4: 1335.
34. Villa-Diaz LG, Nandivada H, Ding J, Nogueira-de-Souza NC, Krebsbach PH, OShea KS, et al. Synthetic polymer coatings for long-term growth of human embryonic stem cells. Nat Biotechnol. 2010; 28: 581-3.
35. Melkoumian Z, Weber JL, Weber DM, Fadeev AG, Zhou Y, Dolley-Sonneville P, et al. Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. Nat Biotechnol. 2010; 28: 606-10.
36. Miyazaki T, Futaki S, Suemori H, Taniguchi Y, Yamada M, Kawasaki M, et al. Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. Nat Commun. 2012; 3: 1236.
37. Rodin S, Antonsson L, Hovatta O, Tryggvason K. Monolayer culturing and cloning of human pluripotent stem cells on laminin-521-based matrices under xeno-free and chemically defined conditions. Nat Protoc. 2014; 9: 2354-68.
38. Crook JM, Peura TT, Kravets L, Bosman AG, Buzzard JJ, Horne R, et al. The generation of six clinical-grade human embryonic stem cell lines. Cell Stem Cell. 2007; 1: 490-4.
39. Unger C, Skottman H, Blomberg P, Dilber MS, Hovatta O. Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum Mol Genet. 2008; 17 (R1): R48-53.
40. Lu HF, Chai C, Lim TC, Leong MF, Lim JK, Gao S, et al. A defined xeno-free and feeder-free culture system for the derivation, expansion and direct differentiation of transgene-free patient-specific induced pluripotent stem cells. Biomaterials. 2014; 35: 2816-26.
41. Nakagawa M, Taniguchi Y, Senda S, Takizawa N, Ichisaka T, Asano K, et al. A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Sci Rep. 2014; 4: 3594.
42. Draper JS, Smith K, Gokhale P, Moore HD, Maltby E, Johnson J, et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol. 2004; 22: 53-4.
43. Buzzard JJ, Gough NM, Crook JM, Colman A. Karyotype of human ES cells during extended culture. Nat Biotechnol. 2004; 22: 381-2; author reply 2.
44. Barbaric I, Biga V, Gokhale PJ, Jones M, Stavish D, Glen A, et al. Time-lapse analysis of human embryonic stem cells reveals multiple bottlenecks restricting colony formation and their relief upon culture adaptation. Stem Cell Reports. 2014; 3: 142-55.
45. Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Narva E, et al. Copy number variation and selection during reprogramming to pluripotency. Nature. 2011; 471: 58-62.
46. Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell. 2011; 8: 106-18.
47. Kono T. Genomic imprinting is a barrier to parthenogenesis in mammals. Cytogenet Genome Res. 2006; 113: 31-5.
48. Bukowiecki R, Adjaye J, Prigione A. Mitochondrial function in pluripotent stem cells and cellular reprogramming. Gerontology. 2014; 60: 174-82.
49. Prigione A, Lichtner B, Kuhl H, Struys EA, Wamelink M, Lehrach H, et al. Human induced pluripotent stem cells harbor homoplasmic and heteroplasmic mitochondrial DNA mutations while maintaining human embryonic stem cell-like metabolic reprogramming. Stem Cells. 2011; 29: 1338-48.
50. Cheng L, Hansen NF, Zhao L, Du Y, Zou C, Donovan FX, et al. Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell. 2012; 10: 337-44.
51. Van Haute L, Spits C, Geens M, Seneca S, Sermon K. Human embryonic stem cells commonly display large mitochondrial DNA deletions. Nat Biotechnol. 2013; 31: 20-3.
52. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med. 2013; 19: 998-1004.
53. Chung S, Shin BS, Hedlund E, Pruszak J, Ferree A, Kang UJ, et al. Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. J Neurochem. 2006; 97: 1467-80.
54. Tang C, Lee AS, Volkmer JP, Sahoo D, Nag D, Mosley AR, et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol. 2011; 29: 829-34.
55. Ben-David U, Nudel N, Benvenisty N. Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. Nat Commun. 2013; 4: 1992.
56. Choo AB, Tan HL, Ang SN, Fong WJ, Chin A, Lo J, et al. Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells. 2008; 26: 1454-63.
57. Ben-David U, Gan QF, Golan-Lev T, Arora P, Yanuka O, Oren YS, et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013; 12: 167-79.
58. Bradley JA, Bolton EM, Pedersen RA. Stem cell medicine encounters the immune system. Nat Rev Immunol. 2002; 2: 859-71.
59. Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet. 2005; 366: 2019-25.
60. Nakajima F, Tokunaga K, Nakatsuji N. Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells. 2007; 25: 983-5.
61. Robertson NJ, Chai JG, Millrain M, Scott D, Hashim F, Manktelow E, et al. Natural regulation of immunity to minor histocompatibility antigens. J Immunol. 2007; 178: 3558-65.
62. Hoglund P, Sundback J, Olsson-Alheim MY, Johansson M, Salcedo M, Ohlen C, et al. Host MHC class I gene control of NK-cell specificity in the mouse. Immunol Rev. 1997; 155: 11-28.
63. Chinen J, Buckley RH. Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol. 2010; 125 (2 Suppl 2): S324-35.
64. Didie M, Christalla P, Rubart M, Muppala V, Doker S, Unsold B, et al. Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest. 2013; 123: 1285-98.
65. Jacquet L, Stephenson E, Collins R, Patel H, Trussler J, Al-Bedaery R, et al. Strategy for the creation of clinical grade hESC line banks that HLA-match a target population. EMBO Mol Med. 2013; 5: 10-17.
66. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011; 474: 212-15.
67. Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2013; 494: 100-4.
68. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol. 2008; 26: 739-40.
69. Dighe V, Clepper L, Pedersen D, Byrne J, Ferguson B, Gokhale S, et al. Heterozygous embryonic stem cell lines derived from nonhuman primate parthenotes. Stem Cells. 2008; 26: 756-66.
70. Duncan MD, Wilkes DS. Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections. Proc Am Thorac Soc. 2005; 2: 449-55.
71. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature. 1984; 307: 168-70.
72. Verda L, Kim DA, Ikehara S, Statkute L, Bronesky D, Petrenko Y, et al. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells. 2008; 26: 381-6.
73. Grinnemo KH, Genead R, Kumagai-Braesch M, Andersson A, Danielsson C, Mansson-Broberg A, et al. Costimulation blockade induces tolerance to HESC transplanted to the testis and induces regulatory T-cells to HESC transplanted into the heart. Stem Cells. 2008; 26: 1850-7.
74. Lui KO, Howie D, Ng SW, Liu S, Chien KR, Waldmann H. Tolerance induction to human stem cell transplants with extension to their differentiated progeny. Nat Commun. 2014; 5: 5629.
75. Pagliuca FW, Millman JR, Gurtler M, Segel M, Van Dervort A, Ryu JH, et al. Generation of functional human pancreatic beta cells in vitro. Cell. 2014; 159: 428-39.
76. Rorsman P, Eliasson L, Kanno T, Zhang Q, Gopel S. Electrophysiology of pancreatic beta-cells in intact mouse islets of Langerhans. Prog Biophys Mol Biol. 2011; 107: 224-35.
77. Rodriguez-Diaz R, Abdulreda MH, Formoso AL, Gans I, Ricordi C, Berggren PO, et al. Innervation patterns of autonomic axons in the human endocrine pancreas. Cell Metab. 2011; 14: 45-54.
78. Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol. 2008; 76: 1352-64.
79. Marastoni S, Ligresti G, Lorenzon E, Colombatti A, Mongiat M. Extracellular matrix: a matter of life and death. Connect Tissue Res. 2008; 49: 203-6.
80. Poon E, Kong CW, Li RA. Human pluripotent stem cell-based approaches for myocardial repair: from the electrophysiological perspective. Mol Pharm. 2011; 8: 1495-504.
81. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013; 499: 481-4.
82. Takebe T, Zhang RR, Koike H, Kimura M, Yoshizawa E, Enomura M, et al. Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant. Nat Protoc. 2014; 9: 396-409.
83. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2011; 470: 105-9.
84. McCracken KW, Cata EM, Crawford CM, Sinagoga KL, Schumacher M, Rockich BE, et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature. 2014; 516: 400-4.
85. Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, Netoff TI, et al. Perfusion-decellularized matrix: using natures platform to engineer a bioartificial heart. Nat Med. 2008; 14: 213-21.
86. Uygun BE, Soto-Gutierrez A, Yagi H, Izamis ML, Guzzardi MA, Shulman C, et al. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med. 2010; 16: 814-20.
87. Ott HC, Clippinger B, Conrad C, Schuetz C, Pomerantseva I, Ikonomou L, et al. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med. 2010; 16: 927-33.
88. Hug K, Hermeren G. Do we still need human embryonic stem cells for stem cell-based therapies? Epistemic and ethical aspects. Stem Cell Rev. 2011; 7: 761-74.
89. Stephenson E, Jacquet L, Miere C, Wood V, Kadeva N, Cornwell G, et al. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat Protoc. 2012; 7: 1366-81.
90. Strelchenko N, Verlinsky O, Kukharenko V, Verlinsky Y. Morula-derived human embryonic stem cells. Reprod Biomed Online. 2004; 9: 623-9.
91. Talaulikar VS, Arulkumaran S. Maternal, perinatal and long-term outcomes after assisted reproductive techniques (ART): implications for clinical practice. Eur J Obstet Gynecol Reprod Biol. 2013; 170: 13-19.
92. Tannenbaum SE, Turetsky TT, Singer O, Aizenman E, Kirshberg S, Ilouz N, et al. Derivation of xeno-free and GMP-grade human embryonic stem cells-platforms for future clinical applications. PLoS One. 2012; 7: e35325.
93. Murdoch A, Braude P, Courtney A, Brison D, Hunt C, Lawford-Davies J, et al. The procurement of cells for the derivation of human embryonic stem cell lines for therapeutic use: recommendations for good practice. Stem Cell Rev. 2012; 8: 91-9.
94. Cyranoski D. Stem-cell pioneer banks on future therapies. Nature. 2012; 488: 139.
95. Baker M. Stem-cell pioneer bows out. Nature. 2011, 479, 459.
96. Hayden EC. Funding windfall rescues abandoned stem-cell trial. Nature. 2014; 510: 18.
97. Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardts macular dystrophy: follow-up of two open-label phase studies. Lancet. 2015; 385: 509-16.
98. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008; 26: 443-52.
99. Sritanaudomchai H, Ma H, Clepper L, Gokhale S, Bogan R, Hennebold J, et al. Discovery of a novel imprinted gene by transcriptional analysis of parthenogenetic embryonic stem cells. Hum Reprod. 2010; 25: 1927-41.